This release is intended for the general public, healthcare professionals, policymakers and other healthcare decision-makers, plus pharmaceutical, policy and trade media.
New analysis of five EU countries as well as Canada, Japan and the UK quantifies what governments stand to gain or lose by 2035 under pro- and contra-innovation policy choices
- Europe risks falling further behind the US and China on R&D investments, clinical trials and access to new medicines
- Cutting investments into medical innovation today could lead to raising overall healthcare spending tomorrow
- Attractive market conditions for new medicines are as much a prerequisite for strategic healthcare autonomy as research and manufacturing
Ingelheim, Germany – EY today released “Innovation at a Crossroads,” a report commissioned by Boehringer, on how policy choices could shape the economy, healthcare systems and strategic autonomy in the EU until 2035. The report assesses France, Germany, Italy, Poland and Spain, as well as EU-level policy, and compares them with Canada, Japan and the UK.
The EY report finds that Europe has significant strengths to draw upon but that policymakers continue to balance a range of competing challenges. These include rising healthcare demand and constrained public finances, as well as the need to strengthen competitiveness, reduce external dependencies and respond to intensifying geopolitical tensions and global competition for investment. Since 2010, EU pharmaceutical R&D spending has grown 4.4% a year, against 5.5% in the US and 20.7% in China, and the European Economic Area's share of commercially sponsored clinical trial starts fell from 22% in 2013 to 12% in 2023. The report concludes that the EU is not losing its science edge as such but is facing challenges in creating the commercial and regulatory conditions required to allow science to translate into economic growth and value.
To explore the consequences of different policy choices, the report sets out two scenarios. In a pro-innovation scenario, governments create predictable conditions through stable intellectual property frameworks, efficient regulation, competitive reimbursement, and support for commercialization. In a contra-innovation scenario, governments introduce cost containment measures that may ease budget pressures in the short run but create higher healthcare costs in the mid- to long-term. The scenarios illustrate the upside and downside of today's policy choices to quantify what countries could gain or lose under different trajectories.
Key findings include:
- Economy: Weaker innovation incentives could impact economic competitiveness and healthcare resilience. R&D investment is fragile and depends on predictable pricing, strong IP protection and efficient regulation. For example, France's corporate R&D expenditure in pharmaceuticals would rise only 14% in the contra-innovation scenario, compared with 66% in the pro-innovation scenario.
- Healthcare: Pharmaceutical innovation can help reduce future healthcare costs, so it should be treated as a long-term investment, not simply as an expense. As an example, in 2035, a pro-innovation path would leave German healthcare spending about 3.1 percentage points of GDP lower than a contra-innovation path, saving around €124 billion.
- Strategic autonomy: Creating the right conditions to support the launch of new pharmaceuticals in Europe is critical to allow Europeans to benefit from the latest medical innovation. To be effective, research & development and local manufacturing capacity should be supported by a commercial environment that retains, scales innovation in domestic markets. The analysis shows that in France, Germany and Italy, a pro-innovation policy path could result in around 390 additional Life Sciences companies being founded per year by 2035 compared with a contra-innovation path, strengthening Europe's domestic innovation ecosystem.
“Pharmaceutical innovations should not be seen simply as a cost for healthcare systems. Innovation allows us to prevent disease, reduce hospital stays, and keep economies productive. This report shows that affordability and innovation are not competing goals but need to be addressed together,” said Shashank Deshpande, Chairman of the Board of Managing Directors, Boehringer Ingelheim.
The report highlights that a coordinated approach, aligning healthcare, industrial, innovation and economic policy, relies on the following requirements: predictable and transparent pricing frameworks, strong and reliable intellectual property protection, and efficient and timely regulatory pathways.
Download the report here: https://www.ey.com/en_uk/industries/life-sciences-innovation-at-a-crossroads
About the “Innovation at a Crossroads” report
The report was commissioned by Boehringer to consider policy developments and their impacts in order to provide a strategic assessment of the policy landscape, rather than a precise quantitative forecast. Based on analysis by EY, the report's policy assessment covers measures introduced or proposed between 2022 and June 2026. The assessment and scenarios rely on a set of assumptions and judgements regarding the potential impact of policies, which are inherently uncertain.
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective. Our approximately 54,300 employees serve over 130 markets to build a healthier tomorrow. Learn more at https://www.boehringer-ingelheim.com (Global) or https://www.boehringer-ingelheim.com/uk (UK).
Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
-
采埃孚再制造首秀进博会 以循环经济赋能汽车产业绿色未来* 采埃孚售后再制造业务首次亮相进博会,集中展示核心零部件再制造技术成果 * 深耕再制造六十余载,以中国为重要支点,持续强化全球再制造网络协同 * 前瞻布局新能2026-11-11
-
Axi joins Babypips as an advertising partner through its Trusted Partner programmeThe arrangement gives Axi an opportunity to introduce its trading services to Babypips' established global audience through its advertising platform2026-11-11
-
200 TOPS稀疏算力!移远SP900BF‑AP搭载高通跃龙™ IQ-9075处理器,领跑端侧AI上海2026年11月11日 美通社 -- 大模型浪潮席卷产业,AI能力正加速从网络端下沉至设备端。工业机器人、产线质检、边缘网关等场景,既渴求强劲本地算力,又对宽温可靠性、2026-11-11
-
百事集团发布中国可持续水资源管理阶段性成果用好水 还好水 农业和生产水效双攀升,累计流域水回馈超11亿升 西安2026年11月11日 美通社 -- 全球领先的食品与饮料企业百事集团,发布中国可持续水资源管理阶段2026-11-11
-
The savings that cost more: new report puts a number on Europe's innovation choiceThis release is intended for the general public, healthcare professionals, policymakers and other healthcare decision-makers, plus pharmaceutical, po2026-11-11
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
锚定健康中国新征程!第一届医药信息传播论坛将于广州启幕
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
华为系具身智能公司具脑磐石完成新一轮融资:对标JEPA,押注类脑智能的认知世界模型
-
北京暑假补习班有哪些?家长首推一对一权威机构金博升学
-
上海高新技术企业代理机构深度访谈与推荐
